Antidepressant monotherapy for bipolar type II major depression
| Autor: | Jay D. Amsterdam, David J. Brunswick |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Adult
Male medicine.medical_specialty Bipolar Disorder medicine.drug_class Adult population Suicide rates behavioral disciplines and activities Bipolar II disorder Fluoxetine Internal medicine mental disorders medicine Humans Psychiatry Biological Psychiatry Depression (differential diagnoses) Clinical Trials as Topic Depressive Disorder Venlafaxine Hydrochloride Mood stabilizer Cyclohexanols medicine.disease Affect Psychiatry and Mental health Practice Guidelines as Topic Antidepressive Agents Second-Generation Antidepressant Female Psychology Selective Serotonin Reuptake Inhibitors Psychopathology |
| Zdroj: | Bipolar Disorders. 5:388-395 |
| ISSN: | 1399-5618 1398-5647 |
| DOI: | 10.1046/j.1399-5618.2003.00066.x |
| Popis: | Objectives: Bipolar type II (BP II) disorder is thought to be distinct from BP I disorder on genetic and biological grounds, and it is not merely a milder form of the illness. It affects 1.5–2.5% of the US adult population, and is characterized by highly recurrent depressive episodes with a substantial morbidity from alcoholism and non-affective psychopathology, and a higher suicide rate than either BP I or unipolar depression. Treatment recommendations for BP II depression are based upon concerns over drug-induced manic-switch episodes, and suggest using either a mood stabilizer alone or a combination of an SSRI plus a mood stabilizer. Recent evidence, however, indicates that the rate of manic switch episodes may be modest in BP II patients. Recent studies have provided evidence that antidepressant monotherapy may be an effective initial and long-term treatment for BP II major depression with a low manic-switch rate. Methods: In this article, we review the recent literature on BP II disorder, with a focus on the treatment of BP II major depression. Results: We present a summary of data from recent studies by our group and others indicating that antidepressant monotherapy for BP II depression may be safe and effective with a low manic-switch rate. Conclusion: Antidepressant monotherapy may be beneficial for some patients with BP II major depression. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|